Advertisement

Picture EBD Group BIO-Europe 2019 Partnering Open BEU2019 650x80px
Organisation › Details

Novo REPAIR Impact Fund (Replenishing and Enabling the Pipeline for Anti-Infective Resistance)

Novo Holdings launches an impact fund commissioned by the Novo Nordisk Foundation with a total budget of USD 165 million to invest in companies involved in discovering and early-stage development of therapies to combat antimicrobial resistance. The fund will focus on priority pathogens as defined by the World Health Organization and the United States Centers for Disease Control and Prevention, a catalogue of 12 families of bacteria that pose the greatest threat to human health. The fund is expected to invest USD 20 million to 40 million per year over 3–5 years in about 20 projects in Europe and the United States, which is anticipated to yield at least one new therapy reaching the market. New approaches to combat antimicrobial resistance urgently need to be developed. Already, more than 700,000 people die each year from infections resistant to most or all antibiotics, and the number is increasing by the day. Antimicrobial resistance is projected to kill more people than cancer does by 2050, which would reduce global economic output by between 2% and 3.5% and severely cripple modern medical and surgical advances. The Novo Nordisk Foundation is commissioning the initiative, and Novo Holdings is executing it. REPAIR is an acronym: Replenishing and Enabling the Pipeline for Anti-Infective Resistance. Read more and watch the project video: www.repair-impact-fund.com *

 

Period Start 2018-02-27 established
  Group Novo Group (Group)
Products Industry venture capital
  Industry 2 anti-infective drug
Person Person Engel, Aleks (Novo 201510 Asset Director at Novo A/S)
     
Region Region København (Copenhagen)
  Country Denmark
  City n. a. København
    Address record changed: 2018-09-12
     
Basic data Employees n. a.
  Currency USD
  Annual sales 165,000,000 (funds, managed (2018) 2018-02-27)
     
    * Document for �About Section�: Novo Holdings A/S. (2/27/18). "Press Release: Novo Holdings Launches USD 165m Impact Fund to Combat Antimicrobial Resistance". Copenhagen.
     
   
Record changed: 2019-06-14

Advertisement

Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px

More documents for Novo Group (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BIO-Europe 2019 Partnering Report BEU2019 650x80px




» top